<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:00:49Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/13086" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/13086</identifier><datestamp>2026-09-24T07:19:08Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Chan, Anthony K.C.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Chander, Ankush</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Blood and Cardiovascular)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:02:20Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:02:20Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2013-06-30</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2013-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/7914</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">8955</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">4269717</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/13086</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/8489</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Unfractionated heparin (UFH) is used as an adjunct during thrombolytic therapy. However, its use is associated with many clinical limitations, such as the inability to inhibit fibrin-bound coagulation factors, increasing the potential for sustained procoagulant activity. We have developed a covalent conjugate of antithrombin (AT) and heparin (ATH) with superior anticoagulant properties to those of UFH. Some advantages of ATH include enhanced inhibition of surface-bound enzymes and its ability to reduce the overall size and mass of clots &lt;em>in vivo&lt;/em>. However, the potential interactions of UFH or ATH with the components of the fibrinolytic pathway are not well understood. Therefore, our study utilized discontinuous second order rate constant (&lt;em>k&lt;sub>2&lt;/sub>&lt;/em>) assays to determine rates of inhibition of plasmin (Pn) in the presence or absence of fibrin by AT+UFH &lt;em>vs.&lt;/em> ATH. In addition, we monitored the rates of Pn generation in a system comprised of preformed fibrin clots with the aim of evaluating the inhibitory effect of AT+UFH or ATH in this more native system. The &lt;em>k&lt;sub>2 &lt;/sub>&lt;/em>values for the inhibition of Pn without fibrin were 5.74x10&lt;sup>6&lt;/sup>±0.278x10&lt;sup>6&lt;/sup> and 6.39x10&lt;sup>6&lt;/sup>±0.588x10&lt;sup>6&lt;/sup> for AT+UFH and ATH, respectively (p=0.36). In the presence of fibrin, the &lt;em>k&lt;sub>2 &lt;/sub>&lt;/em>values decreased to 1.45x10&lt;sup>6&lt;/sup>±0.0971x10&lt;sup>6&lt;/sup> for AT+UFH and 3.07x10&lt;sup>6&lt;/sup>±0.192x10&lt;sup>6 &lt;/sup>for ATH (&lt;em>p&lt;/em>&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MS)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Heparin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Fibrinolysis</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Plasmin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Thrombosis</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Thrombolysis</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Coagulation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Biochemistry</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Hematology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medicinal and Pharmaceutical Chemistry</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Biochemistry</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Interactions of a covalently - linked antithrombin-heparin complex with components of the fibrinolytic pathway</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>